Browsing Tag
MD Anderson Cancer Center
5 posts
Will intravenous oncolytic viruses finally overcome metastatic delivery barriers?
ViroMissile, Inc. expands IDOV-Immune into U.S. cancer centers after FDA IND clearance. Explore what this means for systemic viral oncology.
Chimeric Therapeutics reports early success in frontline cell therapy for AML in ADVENT-AML Phase 1B trial
Chimeric Therapeutics reports promising early results in its ADVENT-AML trial, with 2 of 3 patients showing remission. Find out how CHM is advancing cell therapy.
Pfizer’s BRAFTOVI regimen doubles response rates for metastatic colorectal cancer
Pfizer Inc. has unveiled compelling findings from the Phase 3 BREAKWATER trial, highlighting the efficacy of its BRAFTOVI…
TriSalus Life Sciences’ SD-101 yields positive outcomes from Phase 1 trial in uveal melanoma with liver metastases
TriSalus Life Sciences made a significant contribution to the Society of Immunotherapy for Cancer (SITC) 2023 Annual Meeting…
280Bio initiates Phase 1 clinical study for YL-17231 after FDA approval
In a significant breakthrough for 280Bio, Inc., a clinical-stage biotechnology company, the US Food and Drug Administration (FDA)…